Publisher
Medical Device Regulatory News and Industry Insights
The proposed amendment to Rule 43A of the Drugs Rules, 1945, aims to make imports more convenient by expanding authorised entry points and reducing inland transportation distances.
The Union Ministry of Health and Family Welfare has proposed adding 10 new locations to India’s network of authorised import gateways for drugs, medical devices and cosmetics. The proposal includes eight Inland Container Depots (ICDs), one Special Economic Zone (SEZ) and one international airport.
The move is intended to make the import process more convenient for businesses by allowing consignments to enter closer to manufacturing facilities, warehouses and distribution centres. It is also expected to reduce inland transportation distances, improve logistics efficiency and minimise delays in the movement of healthcare products.
The proposal involves an amendment to Rule 43A of the Drugs Rules, 1945, which specifies the authorised entry points through which drugs can be imported into India.
Which New Import Locations Have Been Proposed?
The Ministry has proposed adding the following locations to the existing list of authorised import gateways:
Haryana: ICD Sonipat, ICD Piyala and ICD Harsaru
Uttar Pradesh: ICD Dadri
Gujarat: ICD Gandhidham/Mundra
Telangana: ICD Sanath Nagar and ICD Thimmapur in Hyderabad
Karnataka: ICD Whitefield in Bengaluru and SEZ Bommasandra
Uttar Pradesh: Noida International Airport for the import of drugs by air
Together, these represent 10 additional locations. The proposed additions will supplement the existing network, which includes ICD Dhannad and ICD Tihi in Indore, Madhya Pradesh, along with airports already notified for drug imports.
What Is the Purpose of Expanding India's Import Gateways?
Under Rule 43A, the entry points notified by the government determine where specified imported products can enter the country.
The proposed expansion is expected to provide importers with more convenient access to authorised locations. Businesses may be able to clear consignments closer to their manufacturing units, warehouses and distribution centres instead of arranging longer inland transportation from existing entry points.
The expected benefits include:
Reduced inland transportation distances
Better logistics and supply chain efficiency
Potential savings in transportation costs
Fewer delays in moving imported consignments
Improved operational convenience for importers
Better movement of medicines, medical devices and cosmetics across different regions
The proposal is also intended to strengthen the infrastructure supporting healthcare product imports and promote ease of doing business.
What Is the Current Status of the Proposed Amendment?
The Ministry has invited objections and suggestions from stakeholders on the draft amendment to Rule 43A of the Drugs Rules, 1945.
Stakeholders can submit their responses to the Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Government of India. Suggestions can also be emailed to drugsdiv-mohfw@gov.in.
The proposed changes will be considered after the Ministry reviews the objections and suggestions received. Therefore, the additional locations should be treated as proposed import gateways until the amendment is finalised and published in the Official Gazette.
For the official announcement, refer to the Ministry of Health and Family Welfare’s press release.
Explore the regulatory requirements and available support with Operon Strategist.
What Does This Mean for Medical Device Importers?
If implemented, the proposed expansion could make import operations more convenient for medical device businesses that depend on international suppliers, components and finished products.
Access to additional authorised entry points may help importers plan transportation and distribution more efficiently. However, the proposal concerns the locations through which imports may enter India. It does not replace the applicable product registration, import licensing, documentation or other regulatory requirements.
Importers should continue to review the requirements that apply to their products and keep track of the final notification before making changes to their import plans.
Importers should also stay informed about India’s regulatory requirements for medical devices. Read our guide to CDSCO Regulatory Compliance to understand the key compliance requirements.
How Operon Strategist Supports Medical Device Market Entry in India
Operon Strategist provides medical device regulatory consulting and global market access support for manufacturers and MedTech innovators. Its services include:
CDSCO medical device registration and regulatory pathway guidance
Regulatory documentation and compliance support
Quality Management System implementation, including ISO 13485
Regulatory strategy for international markets
Support for global product registration and market authorisation
Through its ElevatePlus regulatory and compliance services and MarketEdge global market expansion services, Operon Strategist supports medical device businesses as they plan regulatory approvals and entry into different markets.
Explore CDSCO Medical Device Registration and Global Medical Device Registration to learn more.
Publisher | Medical Device Regulatory News and Industry Insights
The Operon Strategist Editorial Team publishes news, updates, and insights on medical device regulations, regulatory policy changes, and global healthcare industry developments. The team covers key regulatory frameworks, including CDSCO, US FDA, EU MDR, ISO 13485, and international market access requirements, helping medical device manufacturers and healthcare businesses stay informed about evolving regulatory expectations.
